Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
- Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications
- 90% survival rate following Epicel and/or Epicel plus split thickness skin graft
- Study demonstrates that standardized treatment protocols and surgical plans for Epicel use developed by the BRCA result in positive patient outcomes
Excerpt from the Press Release:
CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the publication of results from a retrospective study conducted by the Burn and Reconstructive Centers of America (BRCA) of 40 patients with large posterior trunk burns treated with Epicel® (cultured epidermal autografts) in the Journal of Burn Care & Research. Severe burns on posterior trunk surfaces present special consideration since the posterior surfaces bear the major portion of the body weight. The study evaluated the success of engraftment in patients receiving Epicel for posterior trunk burns with total burn surface area (TBSA) ≥30% treated at three high-volume burn centers within the BRCA between March 2016 and December 2019.
“This valuable first of its kind study shows that the development of standard treatment protocols and surgical plans, based on experience with a high volume of burn patients treated within the Burn and Reconstructive Centers of America, have enabled positive outcomes with cultured epidermal autografts in large severe burns, including posterior burns,” said Bounthavy Homsombath, M.D., Burn Medical Director, Joseph M. Still Burn Center at Doctors Hospital of Augusta.
The retrospective study consisted of 40 patients with a mean age of 38 years (68% male, 32% female) with burn etiology fire/flame (78%).
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?